Browsing Tag
JPMorgan
28 posts
Antofagasta (LON: ANTO): The 2027 production step-change that analysts are debating right now
Antofagasta (LON: ANTO) posted record EBITDA in 2025 as two major Chilean mine expansions target completion in 2027. Here is what retail investors need to know.
Capitec (JSE: CPI) full-year results due 22 April 2026 as earnings surge 20% to 25%
Capitec Bank Holdings (JSE: CPI) publishes FY2026 results on 22 April with earnings up 20-25%. Retail investor roadmap covering valuation, catalysts and risks.
Trump’s Iran speech sends crude to six-year high, gas tops $4 nationwide
U.S. crude oil surged nearly $12 per barrel on April 3, 2026, its largest one-day gain since 2020, after Trump pledged more Iran strikes with no Strait of Hormuz reopening plan.
Brent crude tops $105 as Strait of Hormuz remains shut in largest supply disruption in global oil market history
Oil rises to $105 as US-Israeli war on Iran threatens Gulf export terminals and keeps Strait of Hormuz shut in the biggest supply disruption in history.
Persimmon (LSE: PSN) delivers 12% completion growth and 13% profit rise as vertical integration and brand diversification sharpen competitive edge
Persimmon (PSN) reports 12% volume growth and 13% profit rise in 2025. Analyst buy consensus, 1,600p target. Read the full strategic breakdown.
World’s biggest oil chokepoint closed: What the Iran crisis means for energy prices globally
Iran closes the Strait of Hormuz after US-Israel strikes; Brent crude surges 14% to $83, European gas up 70% as QatarEnergy halts LNG production.
Why Blue Jet Healthcare (NSE: BLUEJET) is spending Rs 1,000cr on Vizag while its stock hovers near IPO price
Blue Jet Healthcare breaks ground on Rs 1,000 crore Vizag API plant as BLUEJET stock trades near lows. What the Rs 2,300 crore expansion means for investors.
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Enanta (NASDAQ: ENTA) prices $65m offering at $10 per share — Is this a lifeline or a warning sign?
Enanta Pharmaceuticals (NASDAQ: ENTA) raises $65M in stock offering at $10 per share. Explore dilution risks, investor sentiment, and future outlook.
PhonePe narrows losses and goes confidential for $1.5bn IPO — Will investors back Walmart’s fintech bet?
Walmart-backed PhonePe trims FY25 losses and files for a $1.5B IPO. Can India’s fintech giant convince investors it’s ready for profitable scale?